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Resumen: Las revistas son básicamente el 
único canal a través del cual los científicos 
pueden hacer que el resultado de su 
investigación sea conocido por sus colegas. 
Las revistas científicas seleccionan la 
información que publican y garantizan su 
calidad mediante un procedimiento doble 
ciego de censura por parte de sus pares. Si 
por un lado este procedimiento parece lógico 
como método para incluir un estudio dentro 
de un campo científico consolidado, también 
es cierto que puede funcionar como un 
mecanismo para la censura. Si, además, un 
campo científico como la farmacología está 
íntimamente vinculado al interés comercial 
de las grandes empresas, las empresas y las 
revistas no solo se convierten en proveedores 
de orientación, sino también en censores que 
ocultan una parte de la verdad y obstaculizan 
el avance científico para defender el interés 
económico de sus patentes. 
   
Palabras clave: Revistas científicas, 
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Abstract: The journals are basically the only 
channel through the scientists can make the 
result of their research know to their colleagues. 
Scientific journals select the information they 
publish and guarantee its quality by means of a 
double blind procedure of censorship by peers. 
If on the one hand this procedure seems logical 
as a method for including a study within a 
consolidated scientific field it is also true that it 
can function as a mechanism for censorship. If, 
furthermore, a scientific field such as 
pharmacology is intimately linked to the 
business interest of large companies then the 
companies and journals not only became 
providers of guidance, but also censors who 
conceal part of the truth and obstruct scientific 
advance to defend the economic interest of 
their patents. 
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If we were to analyze the publishing practices of scientists and their behavior 
from an historical and economic point of view, we would conclude that they do not 
in any way act as rational economic agents. Researchers whose studies are 
published in scientific journals give their work away for free, or even pay to have it 
published. For the journals this constitutes a magnificent publishing deal because 
they do not need to buy the products which they later sell to the scientific 
community at exorbitant prices (Bermejo-Barrera, 2011, pp. 85-96). 
If scientists act this way it is because these journals are basically the only 
channel through which they can make the result of their research known to their 
colleagues, but also because publishing in those journals is the basis of their 
academic and professional prestige, a prestige from which their options for 
promotion within the academic and research fields will stem.  
Scientific journals select the information they publish and guarantee its 
quality by means of a double blind procedure of censorship by peers; in other 
words, they submit each paper to at least two experts who will determine and 
guarantee its value. If on the one hand this procedure seems logical as a method for 
including a study within a consolidated scientific field, it is also true that it can 
function as a mechanism for censorship. In fact, the so-called publication bias is a 
well-known phenomenon in which a study that breaks with the basic ideas of a 
field, or casts a shadow of doubt upon it, is practically impossible to publish, while 
studies contributing mere facts — sometimes almost insignificant — are admitted 
without difficulty in a world where more than three million papers are published 
annually, quantitatively concentrated among the vast fields of chemistry, medicine 
and physics, and to a much lesser extent the social sciences. In fact, the number of 
papers published by social scientists in any one year is equivalent to the number 
published by chemists in just four days.  
Scientific papers are measured by quantity and quality, and their publication 
results in a profitable business, but also in a mechanism of censure and a 
mechanism which can close paths of research when journals close a priori the 
possibility of publishing works of certain orientations for not considering them 
valid. If, furthermore, a scientific field such as pharmacology is intimately linked to 
the business interests of large companies, then the companies and journals not only 
become providers of guidance, but also censors who conceal part of the truth and 
obstruct scientific advance to defend the economic interests of their patents.  
Let us take psychiatry as an example. This field is particularly interesting due 
to the financial benefits linked to it (most psychiatric patients will be medicated for 
life), and due to the fact that here the logic of scientific and clinical research is 
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reversed, because illnesses are catalogued according to the marketing of a specific 
patented molecule, and etiological theories are even created of illnesses based on 
chance pharmacological discoveries.  
Scientific and clinical research generally tries to discover the anatomical, 
physiological, microbiological or other causes of an illness with the purpose of 
taking action against those factors in such a way that once the causes are canceled, 
the clinical symptoms disappear and the disease is cured. For example, when the 
cause of syphilis was discovered, scientists searched for an antibiotic which could 
destroy the agent that caused the disease and thus cure it. 
Medical research requires major investments because it integrates many 
different scientific fields and must be planned and systemized. There have been 
numerous cases, however, analyzed in detail by Lawrence Podolsky, in which a 
discovery came about purely by chance, and one molecule ended up being used 
because it had been effective in alleviating symptoms, although the mechanisms of 
its actions was not fully understood. An example of this was the discovery and the 
effects of acetylsalicylic acid, studied by Podolsky himself (Podolsky, 1997). 
Psychopharmacology is a recent field whose history has been studied by 
such eminent pharmacologists as David Healy (Healy, 1990; 2002), but also by 
psychologists such as Richard P. Bentall (Bentall, 2011), and science historians 
such as Andrew Lakoff (Lakoff, 2005). It is a history with many lights and 
shadows. Lights because many molecules capable of alleviating symptoms have 
been discovered, although none capable of curing any of the so-called mental 
disorders, and shadows because it is often the commercial use of a molecule which 
induces the creation of a theory of the illness, and it is the defense of that particular 
molecule which persuades the pharmaceutical industry into compiling clinical 
information to follow its course, but also to conceal its negative effects. David 
Healy explained this clearly in his monograph on the antidepressant Prozac (Healy, 
2004), and on antidepressants in general (Healey, 1997). 
We will now undertake a brief journey through the history of the first mental 
disorder that generated an enormous commercial success: schizophrenia. We will 
be able to see how this group of illnesses (which have the dubious privilege of 
being considered the strangest of all illnesses) were reduced to an unproven 
biochemical mechanism.  
Schizophrenia was an almost simultaneous discovery of two of the greatest 
psychiatrists of all time: Emil Kraepelin, who was the first to systematize the 
complex map of mental illness, and Eugen Bleuler (Bleuler, 1950). It is a very 
complex group of illnesses, which can be tackled from different fields: 
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pharmacological, psychological, social, etc., as can be seen in the main clinical 
treatise currently in force (Hirsch and Weinberger, 1995). 
Schizophrenia belongs to the group of the psychoses (illnesses not clearly 
organically based, i.e., anatomical, pathological or neurological), which bring about 
the loss of the perception of reality, the loss of the ability to think and speak 
correctly, cause cognitive damage, and lead to social and occupational disability. 
According to Kraepelin, psychoses can be divided into two groups: the 
schizophrenias or early dementias (because contrary to senile dementia they start in 
adolescence and are progressive), and manic depressive psychosis, which don’t 
usually lead to cognitive damage as high as that of the schizophrenias, and are 
characterized by mood disorders which make the patient oscillate among manic 
phases with hallucinations, deliriums and loss of perception of reality and self-
control, and acute depressive phases. This latter psychosis can be dealt with from 
different perspectives: pharmacological, psychological, social, etc., as can be seen 
from its main clinical reference treatise (Goodwin and Jamison, 2007), but it has 
also been the object of an attempt of reduction to an elemental biochemical 
mechanism, as studied by Healey in his history of mania, or bipolar disorder 
(Healey, 2008). 
Let us take a look at how our story develops: 
Eugen Bleuler (Bleuler, 1950) has been the best clinician and researcher of 
the group of the schizophrenias. He called them a “group” because these disorders 
are structured into four different types: 
a) Simple schizophrenia 
b) Paranoid schizophrenia 
c) Hebephrenic schizophrenia 
d) Catatonic schizophrenia 
 
These groups would not be clinically rigid because transitional phases take 
place between the catatonic, paranoid or simple groups, although curiously enough 
nowadays catatonic schizophrenia is rarely observed and is currently considered to 
be a clinical entity by itself. Hebephrenic schizophrenia would be clearly delimited 
because it is associated to certain mental retardation, while those afflicted by 
paranoid or simple schizophrenia tend to have high IQs. 
Bleuler makes a distinction between two types of schizophrenic symptoms: 
the primary or fundamental (Bleuler, pp. 14-93), and the secondary (Bleuler, pp. 94-
226). As we can see, it is a highly complicated set of clinical symptoms that will 
later be greatly simplified. Within the primary group we find: 
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- Alteration of the ability of association. 
- Alteration of affective abilities. 
- Ambivalence of thought and affections. 
- Alterations in the ability to perceive reality: alterations of sensorial        perceptions. 
- Temporal and spatial disorientation. 
- Alterations in memory and sense of time. 
- Alteration of conscience and loss of identity. 
- Alterations of motility. 
- Autism. 
- Loss of the abilities of paying attention and concentration. 
- Alterations of will. 
 
The secondary symptoms (so called because they may be present as part of 
other mental or neurologic disorders) are the following: 
- Hallucinations (basically auditory and to a lesser degree visual). 
- Development of an incidental memory. 
- Alterations of language and writing. 
- Somatic alterations: constipation, headaches, muscular pains, sleep disorders. 
 









- Uncontrolled impulsiveness. 
 
During the acute non-catatonic phases the above symptoms tend to be 
present together with the following: 
- Melancholy (depression). 
- Mania (agitation). 
- Systematic delirium. 
- Crepuscular states. 
- Confusion. 
- Incoherence. 
- Rage and attacks of rage. 
- Flashbacks. 
- Stupor. 
- Development of addiction to alcohol or other substances. 
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Regarding the prognosis, Bleuler established the law of the three thirds, 
which continues to be valid today in spite of the development of medications. 
According to Bleuler, one third of the patients suffer one sole attack and recover, 
another third survive with successively more frequent attacks, and the last third end 
up in a state of dementia. Numerous therapies can be of help in all these cases. In 
1908 with the publication of his book, Bleuler recommended the use of various 
sedatives, along with psychological and social therapies such as the development of 
occupational activities and the reconstruction of social abilities. 
Starting in the 1920s, however, numerous authors began coming up with 
great theories of unification of this complex system of disorders on a misfortunate 
journey which has continued to the present day. Its history has been studied by 
another psychiatrist, Elliot S. Valenstein, in three books where we can observe what 
he has called the war of the soups and the sparks (Valenstein, 1986; 1988; 2005). 
Schizophrenics scare the general public and they also scare physicians. They 
don’t reason; they hallucinate; they become delirious and may be agitated. This is 
why it is essential to tranquilize them or to have them return to reality. In the 
ancient world it was thought that the best way to accomplish this was by means of 
punishment. The dictionary of Hesychius of Alexandria gives the following 
definition for the cure or catharsis: katharthenai, mastigothenai. In English this 
would mean: for purification, flagellation. 
Harsh violence against the mentally ill was applied in the asylums, but 
during the 1920s violence became shock therapies, which have been studied by 
Valenstein (Valenstein, 1986), or mutilations. 
The main protagonists were Ugo Cerletti, the creator of electroshock therapy, 
and other physicians such as L. Medina, who came up with ways of causing 
convulsions among patients in the belief that epileptic seizures were curative. 
Cerletti was of the idea that schizophrenia and epilepsy where contradictory 
and one would cancel out the other; therefore, he thought, producing convulsions 
would cure the patient. He had arrived at this conclusion through a series of 
observations and misinterpretations after watching pigs being slaughtered with 
electric currents and because he had the false idea that there were no schizophrenic 
epileptics, along with the mistaken assumption that the ratio between neurons and 
glial cells is inverse. He began by applying electric shocks to the heads of patients 
without anesthesia. First on one side and then on both, increasing the intensity to 
over 10,000 times what is now believed would be the intensity of a neuronal 
discharge. The rate of mortality was 1% per session, and bone fractures were 
constant until it was decided to administer curare as a muscular relaxant.  
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The number of shocks was established through trial and error and were 
continued to be applied until the patient was no longer violent. This treatment 
became widely used around the world and ended up being applied as a means of 
punishment by nurses and orderlies. Post mortem examinations showed burns 
within brains that had been destroyed, since the degree to which patients were 
tranquilized depended on the amount of brain damage produced by the treatment. It 
was never explained why this therapy was sedative. It was, however, the most 
common treatment around the world — and continues to be used — up till the 
discovery of the first neuroleptic with which we now begin our account.  
Along with electroshock therapy, shocks were also provoked with metrazol 
or insulin to induce hypoglycemic coma. Inoculation with malaria was performed to 
cause an increase in temperature leading to febrile convulsion (Valenstein, 1986). 
Mortality due to insulin induced comas was as high as 10% per session, but 
continued to be used due to its sedative effects, similar to those of the neuroleptics 
and the surgical mutilations. 
The dubious distinction of inventing psychosurgery or cerebral mutilation is 
shared between Walter Freeman and Egas Moniz — a Portuguese neurologist and 
Nobel Prize in medicine whose name was changed so he could become a member 
of the nobility. The procedure was performed by driving a leucotome (or an 
orbitoclast in Freeman’s case, which was essentially an instrument modeled after an 
ice pick) through a hole in the skull or through the tear duct under the eyelid and 
against the top of the eye socket. The instrument would then be swung medially and 
laterally to separate the frontal lobes from the thalamus. The lesions caused by this 
procedure can be seen in the x-rays included in Freeman’s book (Freeman and  
Walls, 1942). Since it was not possible for the surgeon to view the damage that the 
surgical instrument was doing to the brain, it was jokingly said to be the only 
surgery which could be performed with the feet as well as with the hands. One great 
surgeon, Santiago Ramón y Cajal, whose approval had been sought by Egas Moniz, 
considered the technique a senseless brutality, yet it would be disseminated around 
the world, not only for treating schizophrenics, but also alcoholics, sexual 
offenders, and people suffering from all kinds of serious conduct disorders, as can 
be seen in the book by Freeman and Walls. 
The technique was considered acceptable because it was applied in asylums 
to patients confined for life. Freeman and Walls describe the acceptable side effects. 
Although a great percentage of the schizophrenic patient’s intelligence is lost, 
according to the authors it was necessary to reduce it because these patients had an 
excess amount of intelligence (Freeman and Walls, p. 289). Among the side effects, 
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forty-six were persistent, in other words, for life, and in only five cases were 
improvements observed after surgery. 










- Motor retardation. 









- Tendency to play infantile 
games. 
- Mood swings. 
- Sarcasm. 
- Hyperactivity in certain 
cases. 
- Tendency to display 
verbal aggression. 











- Persecution complex. 
- Tendency to blaspheme. 
 
 
These were the acceptable side effects. As we can see, many of them 
coincide with those which Bleuler described as the slow cognitive damage caused 
by acute schizophrenia. Freeman succeeded in causing these symptoms instantly. 
Sadly, not one single cure, not even with the treatments applied by Egas Moniz, can 
be attributed to this mutilation. There were also many cases of death during surgery. 
The patients of Egas Moniz came to him from asylums, and upon their return 
they were submissive. Freeman was a travelling surgeon who preached the benefits 
of his technique, which only required a few minutes after sedation of the patient 
with an electroshock. The proof of his many successes were the Christmas cards 
from the grateful families of his patients. 
Following Freeman and Moniz, lobotomies were performed in almost every 
insane asylum in the civilized world. The cruelty of lobotomies and shock therapies 
explains the success of psychopharmacology, which is only partially effective but 
less cruel at plain sight.  
Psychopharmacology is based on two principles. Every mental disorder has a 
chemical cause, and if we can identify the molecule which causes it, we can 
neutralize it. But this is not possible unless we have a precise catalogue of the 
disorders and their types. This is the purpose of the Diagnostic and Statistical 
Manual of Mental Disorders, known as DSM, based on clinical observations and 
containing a large statistical base. The DSM is modeled on Kraepelin’s concepts 
and is useful as a cataloguing and diagnostic tool, as well as essential for insurance 
companies, for diagnosing occupational disabilities, and for the pharmaceutical 
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companies wishing to associate each disorder with the company’s own proprietary 
molecule. 
All of this is possible through great simplifications. Let us take an example 
from DSM IV-TR (pp. 297-324), where we can see how to diagnose schizophrenia, 
and compare it with Bleuler’s criteria. Symptoms which are to be treated for life 
with antipsychotic medication are the following: 
- Deliriums. 
- Hallucinations. 
- Disorganized language. 
- Disorganized or catatonic conduct. 
- Negative symptoms: affective flattening, apathy, alogia. 
 
It is possible to perform the diagnosis with just two symptoms, especially in 
the case of auditory hallucinations.  
Psychopharmacology has flourished thanks to this system, in conjunction 
with the large pharmaceutical companies and associated with scientific journals and 
medical associations. 
We will briefly chronicle the studies cited by Healey and Valenstein, and 
include data taken from Antoni Talarn (Talarn, ed., 2007), Miguel Jara (Jara, 2007), 
John Read (Read et al., 2006), Allan V. Horwitz (Horwitz, 1992), and from the 
system’s apologists who emphasize the real effects, but conceal the side effects, 
such as Edward Dolnick (Dolnick, 2002). 
The first neuroleptic was chlorpromazine, synthesized by Pierre Deniker by 
adding an atom of chlorine to Promazine (an antihistamine). Administered by 
chance to schizophrenics, physicians observed that it blocked the florid positive 
symptoms, although it was ineffective with the negative symptoms such as 
catatonia. 
Chlorpromazine was first used in Europe, and little by little its negative 
effects became known: it provokes tardive dyskinesia, turning the schizophrenic 
patient into a victim of Parkinson’s. It does not stop deliriums, but does reduce 
hallucinations by 50%. Chlorpromazine was thought to block the neurotransmitter 
dopamine on its way through the frontal lobes. A deficit of dopamine leads to 
Parkinson’s. Its use was much less cruel than the shock therapies and became 
widespread in Europe, but not in the United States until business interests made it 
possible. This occurred when Smith & Kline bought the patent in 1952, and began a 
promotional campaign hiring 300 medical representatives to convince psychiatrists 
of the drug’s virtues. The campaign was so effective than within eight months, two 
million patients were being medicated. Six months later, the number had increased 
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to four million (Valenstein, 1988, 2005). From then on, schizophrenia would be 
considered a chemically based disorder treatable with neuroleptics.  
Thus begins the race of the antipsychotic drugs, which can be studied in the 
books cited above. The use of these drugs can be read in detail in the previously 
cited clinical reference books of Hirsch and Weinberger, and Goodwin and 
Jamison. Then came haloperidol and a series of molecules that were synthesized to 
replace the ones that were losing value as they were becoming generic. This race 
not only uses medical representatives — essential professionals — but also 
colonizes the scientific journals and medical associations. 
Let us take a look at some facts: 25% of the budget of the American 
Psychiatric Association’s conventions are financed by the pharmaceutical industry, 
which pays for conferences and travel expenses. In 1988, $86 million were spent on 
publicity in the Association’s annual conference, and $1.9 million on the following 
journals:  




That same year, two million dollars were spent on the education of 
psychiatrists, and $469.000 in scholarships for psychiatry residents. The industry 
spent $130 billion on research, and the Federal Government spent $200 billion. 
In 1994, the pharmaceutical industry spent $150 billion on six thousand 
research projects protected by confidentiality clauses with the objective of 
concealing any negative information regarding their molecules. Furthermore, 34% 
of the authors of articles published in the following magazines had financial 





The New England Journal of Medicine 
Proceedings of the National Academy of Medicine 
 
The pharmaceutical companies are the only ones who can afford the costly 
research. They attempt to contribute to the improvement of medications and mental 
health, but they are under the pressure of the law of the market and thus search for 
molecules which will be profitable due to their elevated price and mass use, 
molecules that must be replaced when the previous ones become generic. 
The introduction of a new drug may be accompanied by deception. An 
example would be Zyprexa, an antidopaminergic, antihistaminergic, anticholinergic 
and antiserotoninergic, recommended for schizophrenia, bipolar disorder, 
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depression and anxiety (Healy, 2008). Upon the drug’s approval, the Brief 
Psychiatric Rating Scale established that out of 18 symptoms (without 
differentiating primary from secondary) on a scale from 1 to 7, after six weeks of 
administration, there was an average improvement of 2.82% of the 126 possible 
items, without specifying which. It is denied that the drug may produce tardive 
dyskinesia, as was the case with previous antipsychotics, but it is not possible to 
know this for sure in such a short span of time because this malady appears after 
long use of a drug, sometimes after many years. Furthermore, no information was 
given as to whether the patients were receiving other prior treatments, something 
essential for making conclusions, nor was any information given regarding the 
duration of the disorder (Valenstein, 2005). None of this, however, has prevented 
the massive commercialization of this drug whose side effects will be 
communicated to the manufacturer by psychiatrists bound to contracts protected by 
xxx confidentiality clauses. 
We could narrate countless such stories, like that of the SSRI (Selective 
Serotonin Reuptake Inhibitors), which have succeeded in making the general public 
believe that every acute case of sorrow is a case of depression (Horwitz and 
Wakefield, 2007; Illouz, 2008), and that there are scarcely any psychological 
factors at work in depression or anxiety, even though drugs are only effective in 
50% of those patients who are treated with drugs without receiving psychotherapy, 
but in 80% of patients in which drugs are combined with psychotherapy, something 
that is chemically unexplainable (Cia, 2007). According to Richard Bentall, 
placebos have a similar rate of effectiveness (Bentall, 2011).  
Eli Lily’s success with its Prozac was the result of marketing it together with 
the serotonergic theory of the disorder, thanks to the publication of 50,000 copies of 
its manual for family practitioners — the professionals in charge of prescribing the 
drug because they are more numerous than psychiatrists. Family practitioners are 
permitted to prescribe drugs with a quick diagnosis following the guidelines of 
DSM IV. 
If depression were simply due to a lack of serotonin, could we then say that 
headaches are a result of a lack of acetylsalicylic acid? Obviously not, although it 
tends to alleviate headaches just as Prozac sometimes alleviates the symptoms of 
depression — without acting upon its root causes. This view is comprehensible, 
though, if we take into account that the symptoms of depression correspond in part 
to those of the neuroses of old, which are no longer part of any clinical chart, or to 
the classic melancholia. Eli Lily, however, sold $2.5 billion worth of Prozac in 1996 
alone, of which $1.73 billion were sold in the United States. Its competitor, Pfizer’s 
Zoloft, sold one billion dollars, thus totaling sales of $4.5 billion of SSRIs in that 
one year. 
The clinical use of these drugs has increased quickly. In 1996 there were 
600,000 children in the United States medicated with Zoloft, Paxil and Prozac, an 
annual increase of 298%. The same occurred with Ritalin — the miracle cure for 
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attention deficit disorder — with 2.5 million children under medication in 1995, a 
full 5% of the school age population, compared to 3% the previous year. Then we 
have the antipsychotic Zyprexa used for treating restless fetuses, as described by 
David Healy (Healy, 2008). 
It is obvious that advances in psychopharmacological research, clinical use 
of drugs and financial interests go hand in hand. The problem comes when those 
interests establish absolute control, concealing the side effects of the drugs they 
place in the market, promoting them as miracle cures to an ever greater number of 
people for the sole purpose of earning greater profits, and denying the complex 
nature of the so-called mental disorders in areas as complicated as sexuality, the 
thinking process, language, social and occupational problems, religious ideas, etc.  
Psychiatric research has a complex epistemology which has been the object 
of study by numerous authors such as Rachel Cooper (Cooper, 2007), Jennifer 
Radden (Radden, 2004), Edward M. Hundert (Hundert, 1990), Maxwell Bennet 
(Bennet, 2007), and Tulio Maranhao (Maranhao, 1986). It is not possible to search 
for simple causes, but this is exactly what is being done thanks to a great 
reductionist process and to the control which the large publishing concerns have 
managed to establish over the field of psychiatry. The journals published by these 
companies are now considered the only depositories of scientific truth. They are 
protected by their publishers, and they are financed by the pharmaceutical industry 
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